Clinical Trial Update: Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a gene therapy aimed at treating Leber Congenital Amaurosis (LCA) across Phase 1/2, with completion and results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Drugs mentioned

• MeiraGTx gene therapy (unspecified product)

Snippet

Sponsor: MeiraGTx UK II Ltd | Conditions: Leber Congenital Amaurosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-08